A.CURE Introduction
1. Core Technology
A.CURE specializes in AI-powered voice biomarker analysis for the early detection and severity prediction of heart failure. Its flagship product, Heart to Voice, offers:
- Non-invasive diagnostics: Utilizing voice data to predict heart failure severity in four stages (Normal, Mild, Moderate, Severe) with 90.4% accuracy.
- Scalable pipeline: Expanding applications to other conditions such as kidney failure, developmental disorders, and cognitive impairments.
- AI innovation: Combining advanced AI models (CNN, Transformer) with clinical data for precise health monitoring.

2. Validation
- Clinical trials with 112 patients demonstrated a 90.4% accuracy rate in detecting heart failure using AI voice analysis.
- Patents filed in 157 countries for proprietary AI voice biomarker technology.
- Recognized with the "Paul Dudley White International Scholar Award" at the World Congress of Cardiology 2023.

3. Team Members
- CEO: Kyungho Jung
Formerly with Aimmed and Hanmi Science, bringing expertise in healthcare innovation and business leadership.
- CMO: Eungjoo Kim, M.D.
Head of Cardiology at Korea University Guro Hospital, specializing in heart failure diagnosis and treatment.
- AI Advisor: Hansuk Kyo, Ph.D.
Professor at Korea University and Director of the Intelligent Systems Lab, leading AI development.
- Legal Counsel: Sunghwan Oh
Overseeing corporate legal affairs and compliance.

Company Overview
Founded in June 2024, A.CURE is committed to revolutionizing healthcare through accessible AI-driven diagnostic solutions while building partnerships with global medical institutions and technology leaders.

에이닷큐어 a.cure

Org chart

Teams

Offices

에이닷큐어 a.cure

Org chart

Teams

Offices

Related companies